Eli Lilly (LLY.US) stock fell nearly 4% after the drugmaker posted disappointing quarterly figures. Company earned $1.87 per share which came well below analysts’ expectations of $2.14 a share. Lilly reported revenue of $6.81 billion in the first quarter, short of the average market estimate of $7.02 billion. Company recorded a 7% fall in quarterly profit, due to higher spending on research and development of treatments including Covid-19 drugs. Also Lilly took various asset impairment charges during the quarter, as well as incurring costs related to its acquisition of Prevail Therapeutics. The company also lowered its full-year earnings forecast due to lower demand for its COVID-19 antibody therapies with the U.S. vaccine rollout in full swing. Drugmaker now expects adjusted full-year earnings of $7.80 to $8.00 per share, from its prior forecast of $7.75 to $8.40 per share.
Eli Lilly (LLY.US) stock launched today’s session with a bearish price gap and is currently testing lower limit of the ascending channel. Should break lower occur, then downward move may be extended to the support at 173.83. On the other hand, if buyers will manage to halt declines here, then another upward move towards major resistance at $197.28 is possible. Source: xStation5
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile appThis content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
